SCHEMBL2029804

SCHEMBL2029804

CCCC/C=C\CCCCCCCC(=O)OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.73
F7 P08709 2/20 0.63
F3 P13726 2/20 0.63
LMNA P02545 2/20 0.61
ALDH1A1 P00352 1/20 0.61
CNR2 P34972 1/20 0.59
TERT O14746 3/20 0.58
PTPN1 P18031 3/20 0.58
PPARG P37231 3/20 0.58
PPARD Q03181 3/20 0.58
PPARA Q07869 3/20 0.58
CYP1A2 P05177 2/20 0.58
MAPT P10636 2/20 0.58
CYP2C19 P33261 2/20 0.58
BLM P54132 2/20 0.58
HSD17B10 Q99714 2/20 0.58
FABP4 P15090 2/20 0.58
FAAH O00519 2/20 0.58
KMT2A Q03164 2/20 0.58
GMNN O75496 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28248477 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL10444384 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL3705115 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL28495765 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL583629 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL28813484 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL583630 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL30801443 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL31512544 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1
SCHEMBL28344532 1.00 EPHX2 (0.73) EPHX2F7F3LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025090952-A1 DESATURASE VARIANTS AND METHODS OF USE GENOMATICA, INC. (US) 2025-05-01 WO claimed
CN-119827660-A Identification method of kitchen waste grease 武汉食品化妆品检验所 2025-04-15 CN claimed
US-20240287015-A1 Method for Producing an Ionizable Lipid NANOVATION THERAPEUTICS INC. (CA) 2024-08-29 US claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
EP-3377465-B1 PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS PROVIVI INC (US) 2023-08-02 EP claimed
CN-115404118-B Aluminum shell stretching oil composition 季华实验室 2023-04-18 CN claimed
WO-2022246555-A1 METHOD FOR PRODUCING AN IONIZABLE LIPID NANOVATION THERAPEUTICS INC. (CA) 2022-12-01 WO claimed
CN-115404118-A Aluminum shell stretching oil composition 季华实验室 2022-11-29 CN claimed
CN-115215748-A Production of aliphatic olefin derivatives by olefin metathesis 普罗维维公司 2022-10-21 CN claimed
CN-108473390-B Production of aliphatic olefin derivatives by olefin metathesis 普罗维维公司 2022-08-09 CN claimed
CN-109999019-B Application of myristoleic acid methyl ester in preparation of product for preventing or treating metabolic syndrome or improving body energy metabolism 中国科学院动物研究所 2021-11-16 CN claimed
US-9776179-B2 Production of fatty olefin derivatives via olefin metathesis PROVIVI, INC. (US) 2017-10-03 US claimed
US-20170137365-A1 PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS PROVIVI, INC. (US) 2017-05-18 US claimed
WO-2008005831-A2 COMPOSITIONS OF PPO-INHIBITING COMPOUNDS AND N-ALKYLPYRROLIDONES FMC CORPORATION (US) 2008-01-10 WO claimed
WO-2026104850-A1 POLYOL ESTERS INNOSPEC LIMITED (GB) 2026-05-21 WO disclosed
WO-2026104830-A1 USES AND COMPOSITIONS INNOSPEC LIMITED (GB) 2026-05-21 WO disclosed
WO-2026104852-A1 USE OF A POLYOL ESTER FOR INCREASED WATER REPELLENCY, REDUCED FRICTION, OR IMPROVED VISUAL APPEARANCE, METHOD OF TREATING A SURFACE, COMPOSITION AND TREATED SUBSTRATE INNOSPEC LIMITED (GB) 2026-05-21 WO disclosed
US-4185027-A Hydrolysis of methyl esters THE PROCTER & GAMBLE COMPANY (US) 1980-01-22 US disclosed
EP-0002545-A1 Process for separating esters of fatty acids by degree of unsaturation THE PROCTER & GAMBLE COMPANY (US) 1979-06-27 EP disclosed
EP-0001854-A2 Process for separating unsaturated and saturated fatty acid esters THE PROCTER & GAMBLE COMPANY (US) 1979-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137365-A1 PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS SREBF1, F2, SREBF2 EPHX2 929/4885F7 70/4885F3 72/4885
US-20240287015-A1 Method for Producing an Ionizable Lipid CEL, FASN, COASY EPHX2 1060/4885F7 259/4885F3 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.